☆ 4.6 Review

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

CELLS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa et al.

Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance

Mahmoud R. Gaballa et al.

Summary: In newly-diagnosed MM patients, the use of VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance therapy is associated with favorable outcomes. Significant increases in CR/sCR rates and ≥VGPR rates were observed at day-100 post-transplant and at the last evaluation. The 5-year PFS and OS were 43.1% and 79%, respectively.

LEUKEMIA & LYMPHOMA (2022)

添加到收藏夹

Article Hematology

Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost

Kevin Y. Chen et al.

Summary: The addition of plerixafor (P) to granulocyte colony stimulating factor (G-CSF) during peripheral blood mobilization of hematopoietic stem cells (HSC) increases the number of patients meeting collection goals prior to autologous stem cell transplant (aSCT). However, the use of P is not universally adopted due to cost concerns. This study compares the clinical and financial impacts of using an algorithm-based P mobilization strategy versus its use in all patients. The results show that upfront use of P significantly reduces the number of apheresis days and increases HSC collection yield without increasing overall cost per patient.

TRANSFUSION AND APHERESIS SCIENCE (2022)

添加到收藏夹

Review Hematology

Knowing the unknowns in high risk multiple myeloma

Benjamin A. Derman et al.

Summary: The optimal approach to the treatment of high risk multiple myeloma remains unclear due to variable definitions and limited studies dedicated to its treatment.

BLOOD REVIEWS (2022)

添加到收藏夹

Article Oncology

Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient

Vadlamani Surya Prakash et al.

Summary: This study prospectively evaluated the use of plerixafor for stem cell mobilization in multiple myeloma patients. The results showed that using plerixafor in combination with G-CSF resulted in a higher success rate and cost savings compared to using G-CSF alone.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

添加到收藏夹

Article Hematology

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Ibai Goicoechea et al.

Summary: An analysis of patients with multiple myeloma revealed that undetectable measurable residual disease (MRD) predicts higher progression-free survival, and identified differences in MRD resistance mechanisms between patients with standard and high-risk cytogenetic abnormalities.

BLOOD (2021)

添加到收藏夹

Article Biophysics

Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT

Nico Gagelmann et al.

Summary: The study found that for patients with t(4;14), tandem autologous and tandem autologous/reduced-intensity allogeneic transplantation were associated with better progression-free survival (PFS), while for patients with del(17p), there was no significant difference in outcome.

BONE MARROW TRANSPLANTATION (2021)

添加到收藏夹

Article Oncology

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Hartmut Goldschmidt et al.

Summary: The efficacy of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) has not been clearly defined in the era of continuous novel agent treatment, however, patients who received this treatment may have benefited.

LEUKEMIA (2021)

添加到收藏夹

Meeting Abstract Hematology

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Hartmut Goldschmidt et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI plus Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial

Martin F. Kaiser et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Noemi Puig et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD ResponseAdapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Luciano J. Costa et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

Jonathan L. Kaufman et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)

Aurore Perrot et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

Larry D. Anderson et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation AntigenDirected Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Thomas Martin et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Hartmut Goldschmidt et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Laura Rosinol et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Herve Avet Loiseau et al.

BLOOD (2021)

添加到收藏夹

Article Hematology

OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)

Rakesh Popat et al.

Clinical Lymphoma Myeloma & Leukemia (2021)

添加到收藏夹

Article Hematology

OAB-004: Carfilzomib-based induction/consolidation with or without autologous transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) maintenance: efficacy in high-risk patients of the FORTE study

Roberto Mina et al.

Clinical Lymphoma Myeloma & Leukemia (2021)

添加到收藏夹

Article Hematology

OAB-015: Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk

Ruth De Tute et al.

Clinical Lymphoma Myeloma & Leukemia (2021)

添加到收藏夹

Article Oncology

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Marc-Andrea Baertsch et al.

Summary: In patients with multiple myeloma post autologous stem cell transplantation, maintenance treatment with bortezomib and lenalidomide showed no significant difference in progression-free survival and overall survival.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Oncology

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

M. A. Dimopoulos et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

Francesca Gay et al.

Summary: This study aimed to evaluate the efficacy and safety of different carfilzomib-based treatment approaches and maintenance therapy, showing that KRd plus ASCT demonstrated superiority in improving responses compared with other treatments, and carfilzomib plus lenalidomide as maintenance therapy improved progression-free survival compared with lenalidomide alone.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Cell & Tissue Engineering

Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry

Mohamed-Amine Bekadja et al.

Summary: This study compared the outcomes of patients undergoing autologous transplantation using PBSCs stored at 4 degrees C with cryopreserved PBSCs, showing significant differences in neutrophil and platelet engraftment speed but no significant differences in other outcomes.

CYTOTHERAPY (2021)

添加到收藏夹

Article Hematology

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel et al.

Summary: The study shows that using carfilzomib, lenalidomide, and dexamethasone in combination with transplant treatment for eligible patients with newly diagnosed multiple myeloma can produce rapid and deep responses, with an acceptable safety profile. Close monitoring of cardiovascular adverse events is necessary.

BLOOD (2021)

添加到收藏夹

Article Oncology

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial

Ola Landgren et al.

Summary: The study assessed the safety and effectiveness of carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy for newly diagnosed multiple myeloma patients. Results showed that 71% of patients achieved the primary endpoint of minimal residual disease (MRD) negativity in the bone marrow, indicating the success of the treatment.

JAMA ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).

Kwee Yong et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

Pieter Sonneveld et al.

Summary: Consolidation treatment with VRD followed by lenalidomide maintenance improves PFS and depth of response in newly diagnosed patients with multiple myeloma compared to maintenance alone.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau et al.

Summary: The CASSIOPEIA study compared daratumumab maintenance with observation only in newly diagnosed multiple myeloma patients, showing that daratumumab maintenance every 8 weeks for 2 years significantly reduced the risk of disease progression or death. Longer follow-up and other ongoing studies are needed to further understand the optimal daratumumab-containing post-ASCT maintenance treatment strategy.

LANCET ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods

Jill Corre et al.

LEUKEMIA (2021)

添加到收藏夹

Article Oncology

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Stefania Oliva et al.

Summary: Minimal residual disease (MRD) detection by multiparameter flow cytometry (MFC) is a strong prognostic factor in assessing deep response in multiple myeloma patients, with MRD negativity significantly correlated with improved survival rates and reduced risk of progression or death. Lenalidomide maintenance therapy can further enhance the rate of MRD negativity.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Hematology

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

Benjamin Diamond et al.

Lancet Haematology (2021)

添加到收藏夹

Article Hematology

Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation-A Blood or Marrow Transplant Survivor Study Report

Smith Giri et al.

Summary: The study revealed a significant decline in late cause-specific mortality among multiple myeloma patients receiving autologous peripheral blood stem cell transplantation over the past 25 years, including decreases in myeloma-, infection-, and cardiovascular disease-related mortality.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Hematology

The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience

Iuliana Vaxman et al.

Summary: The study reported outcomes of 117 patients with newly diagnosed multiple myeloma who received novel agent induction and underwent stem cell transplantation using chemotherapy mobilization. Chemo-mobilization improved stem cell collection without adverse impact on patient safety and post-transplant clinical course.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Oncology

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

Bruno Paiva et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

Hartmut Goldschmidt et al.

LEUKEMIA (2020)

添加到收藏夹

Article Hematology

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees et al.

BLOOD (2020)

添加到收藏夹

Article Oncology

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma

Nisha S. Joseph et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).

Parameswaran Hari et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Hematology

A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis

D. Laszlo et al.

TRANSFUSION AND APHERESIS SCIENCE (2020)

添加到收藏夹

Article Oncology

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Brian G. M. Durie et al.

BLOOD CANCER JOURNAL (2020)

添加到收藏夹

Article Hematology

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Jagoda K. Jasielec et al.

BLOOD (2020)

添加到收藏夹

Article Hematology

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michele Cavo et al.

LANCET HAEMATOLOGY (2020)

添加到收藏夹

Article Oncology

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Shaji K. Kumar et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Defining and Managing High-Risk Multiple Myeloma: Current Concepts

Luciano J. Costa et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

添加到收藏夹

Article Hematology

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Paola Tacchetti et al.

Lancet Haematology (2020)

添加到收藏夹

Article Hematology

High-risk myeloma: a challenge to define and to determine the optimal treatment

Charlotte Pawlyn

Lancet Haematology (2020)

添加到收藏夹

Article Hematology

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Saad Z Usmani et al.

Lancet Haematology (2020)

添加到收藏夹

Article Hematology

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

Nikhil C. Munshi et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Meeting Abstract Hematology

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Followup Analysis of the IFM 2009 Trial

Aurore Perrot et al.

BLOOD (2020)

添加到收藏夹

Meeting Abstract Hematology

Fresh Versus Cryopreserved Peripheral Stem Cell for Autologous Transplantation in Multiple Myeloma: An Analysis of Short-Term Outcomes

Jacinth Joseph et al.

BLOOD (2020)

添加到收藏夹

Article Hematology

Long-term outcomes after autologous stem cell transplantation for multiple myeloma

Katherine K. Nishimura et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Medicine, General & Internal

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau et al.

LANCET (2019)

添加到收藏夹

Article Hematology

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Laura Rosinol et al.

BLOOD (2019)

添加到收藏夹

Article Oncology

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

Edward A. Stadtmauer et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios A. Dimopoulos et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Graham H. Jackson et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial

H. Goldschmidt et al.

LEUKEMIA (2018)

添加到收藏夹

Letter Biophysics

Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma

Rahul Naithani et al.

BONE MARROW TRANSPLANTATION (2018)

添加到收藏夹

Article Biophysics

Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy

M. Sarmiento et al.

BONE MARROW TRANSPLANTATION (2018)

添加到收藏夹

Article Biophysics

Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas

Amado Kardduss-Urueta et al.

BONE MARROW TRANSPLANTATION (2018)

添加到收藏夹

Article

Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant

Uday Kulkarni et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)

添加到收藏夹

Meeting Abstract Hematology

Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib plus Lenalidomide plus Dexamethasone or Bortezomib plus Thalidomide plus Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma

Laura Rosinol Dachs et al.

BLOOD (2018)

添加到收藏夹

Article Hematology

Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents

Helgi van de Velde et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2017)

添加到收藏夹

Article Oncology

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Philip L. McCarthy et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Michel Attal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Hematology

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

Sarah A. Holstein et al.

LANCET HAEMATOLOGY (2017)

添加到收藏夹

Article Oncology

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis

Nikhil C. Munshi et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. Moreau et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Hematology

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau et al.

BLOOD (2016)

添加到收藏夹

Article Hematology

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Gordon Cook et al.

LANCET HAEMATOLOGY (2016)

添加到收藏夹

Article Oncology

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Francesca Gay et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Review Hematology

Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations

Sergio Giralt et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)

添加到收藏夹

Article Oncology

High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Multiple Myeloma: A Single Institution Experience at All India Institute of Medical Sciences, New Delhi, Using Non-Cryopreserved Peripheral Blood Stem Cells

Smita Kayal et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)

添加到收藏夹

Article Medicine, General & Internal

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

A. Palumbo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Oncology

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma

Heinz Ludwig et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Hematology

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Laura Rosinol et al.

BLOOD (2012)

添加到收藏夹

Article Medicine, General & Internal

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Michel Attal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Hematology

An automatic wash method for dimethyl sulfoxide removal in autologous hematopoietic stem cell transplantation decreases the adverse effects related to infusion

Andres Sanchez-Salinas et al.

TRANSFUSION (2012)

添加到收藏夹

Article Medicine, General & Internal

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

Michele Cavo et al.

LANCET (2010)

添加到收藏夹

Article Hematology

Improved survival in multiple myeloma and the impact of novel therapies

Shaji K. Kumar et al.

BLOOD (2008)

添加到收藏夹

Article Hematology

Recent major improvement in long-term survival of younger patients with multiple myeloma

Hermann Brenner et al.

BLOOD (2008)

添加到收藏夹

Review Oncology

Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review

L. Wannesson et al.

ANNALS OF ONCOLOGY (2007)

添加到收藏夹

Article Oncology

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321

B Barlogie et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

添加到收藏夹

Article Oncology

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the group myelome-autogreffe

J Fermand et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

添加到收藏夹

Article Hematology

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy:: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

J Bladé et al.

BLOOD (2005)

添加到收藏夹

Article Hematology

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

A Palumbo et al.

BLOOD (2004)

添加到收藏夹

Article Medicine, General & Internal

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

JA Child et al.

NEW ENGLAND JOURNAL OF MEDICINE (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.